LONDON, January 19, 2017 /PRNewswire/ --

Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics and Others

The global anti-obesity drugs market is expected to grow at a CAGR of 27.1% in the first half of the forecast period and CAGR of 38.7% in the second half of the forecast period. The market is expected to grow at a CAGR of 32.8% from 2016 to 2027. The market is estimated at $1,058 million in 2016, $3,513 million in 2021, and $24,063 million in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 205-page report you will receive 78 tables and 140 figures - all unavailable elsewhere.

The 205-page report provides clear detailed insight into the global anti-obesity drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Global Anti-Obesity Drugs market forecasts from 2017-2027

• Anti-Obesity Drugs National market forecasts from 2017-2027, covering:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
- China
- India
- Brazil
- Russia
- RoW

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

• Anti-Obesity Drugs submarket forecasts from 2017-2027, by Mechanisms of Action:
- Incretin mimetics/GLP-1 agonists
- SNDRIs
- Lipase inhibitors
- Serotonin receptor agonists
- Sympathomimetic-GABA receptor agonists
- Sympathomimetics
- Others

• Anti-Obesity Drugs submarket forecasts from 2017-2027, by Duration of Therapy:
- Short-term Drugs
- Long-term Drugs

• Anti-Obesity Drugs submarket forecasts from 2017-2027, segmented by Innovator vs Generic Drugs

• Anti-Obesity Drugs submarket forecasts from 2017-2027, segmented by Prescription vs OTC Drugs

• Analysis of the key factors driving and restraining the growth of the anti-obesity drugs market from 2017-2027

• Pricing and Reimbursement overview of the anti-obesity drugs market

• Assessment of selected leading companies that hold major market shares in the anti-obesity drugs market.

Visiongain's study is intended for anyone requiring commercial analyses for the Anti-Obesity Drugs Market and leading companies. You find data, trends and predictions.

Buy our report today Global Anti-Obesity Drugs Market Forecast 2017-2027: Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics and Others.

To request a report overview of this report please emails Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1772/Global-Anti-Obesity-Drugs-Market-Forecast-2017-2027

List of Companies and Organisations Mentioned 

ADial Pharmaceuticals

Akrimax Pharmaceuticals

Arena Pharmaceuticals

AstraZeneca

Biophytis

Boehringer Ingelheim

Boston Therapeutics

Diasome

Eisai

EMEA

Empros Pharma

FDA

GenePreDiT

GlaxoSmithKline (GSK)

Hanmi

Ildong Pharmaceuticals

Intarcia Therapeutics

Ionis Pharmaceuticals

Janssen Pharmaceuticals

KT&G Life Sciences

Kwang Dong

Medivation

Medlab Clinical

Neothetics

NGM Biopharmaceuticals

Novartis

Novo Nordisk

OPKO Health

Orexigen

Rhythm Pharmaceuticals

Roche

Saniona

Shionogi & Co., Ltd

Takeda

Teva

Valeant Pharmaceuticals

Virtici

Vivus

Xenetic Biosciences

Zafgen

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

SOURCE Visiongain Ltd